Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research note issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Sangamo Therapeutics in a report on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, Sangamo Therapeutics has a consensus rating of “Hold” and an average target price of $5.67.

Sangamo Therapeutics Trading Up 6.0 %

NASDAQ SGMO opened at $0.92 on Friday. The firm’s fifty day simple moving average is $0.50 and its two-hundred day simple moving average is $0.61. Sangamo Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.48. The firm has a market capitalization of $190.22 million, a P/E ratio of -0.49 and a beta of 1.24.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative return on equity of 182.55% and a negative net margin of 1,749.06%. The firm had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $8.51 million. During the same period in the prior year, the firm posted $0.12 earnings per share. As a group, sell-side analysts predict that Sangamo Therapeutics will post -0.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

Large investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System boosted its holdings in Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 23,650 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Sangamo Therapeutics by 72.4% in the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 31,003 shares during the last quarter. Golden State Equity Partners boosted its holdings in Sangamo Therapeutics by 21.0% in the fourth quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 34,960 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Sangamo Therapeutics by 14.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 129,811 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Sangamo Therapeutics by 4.0% in the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after purchasing an additional 192,385 shares during the last quarter. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.